Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 472 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the transaction, the insider now owns 17,331 shares in the company, valued at $512,650.98. The trade was a 2.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.42, for a total value of $9,166.24.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $0.13 during mid-day trading on Tuesday, hitting $31.12. The stock had a trading volume of 14,635,490 shares, compared to its average volume of 9,946,161. The firm has a market cap of $6.80 billion, a PE ratio of 70.09 and a beta of 1.25. The company has a 50 day moving average of $25.02 and a two-hundred day moving average of $21.06. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue was up 77.1% compared to the same quarter last year. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. Renaissance Technologies LLC boosted its stake in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the period. Geode Capital Management LLC grew its stake in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after purchasing an additional 328,142 shares in the last quarter. Finally, State of Michigan Retirement System lifted its stake in shares of Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after purchasing an additional 320,000 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday. They set an “overweight” rating and a $42.00 target price on the stock. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.